BiomX is a clinical‐stage biotechnology company focused on developing precision microbiome therapies through targeted bacteriophage research. The company’s proprietary platform combines microbial genomics, artificial intelligence and high‐throughput screening to identify and engineer phage therapies aimed at specific bacterial strains that drive dysbiosis in human diseases. By harnessing naturally occurring phages, BiomX seeks to restore healthy microbial communities without the broad‐spectrum effects associated with traditional antibiotics.
The company’s pipeline includes programs in dermatology and gastroenterology, with lead candidates targeting Cutibacterium acnes strains implicated in acne vulgaris, as well as novel approaches to address pathogenic biofilms in inflammatory bowel disease. Each program leverages BiomX’s phage libraries and machine learning algorithms to optimize potency, safety and manufacturability. In preclinical and early clinical studies, the platform has demonstrated selectivity for disease‐associated bacteria while sparing beneficial microbiota, positioning BiomX at the forefront of next‐generation anti‐infectives.
Founded in 2015 in Tel Aviv, Israel, BiomX has expanded its global footprint with R&D operations in Cambridge, Massachusetts and manufacturing partnerships across North America and Europe. The company has established collaborations with leading academic institutions and industry partners to accelerate discovery and scale production. Over the years, BiomX has advanced multiple phage candidates through regulatory milestones, reflecting its commitment to rigorous science and robust clinical development.
BiomX is led by a management team with extensive experience in biotechnology, pharmaceutical development and commercial strategy, and guided by an independent board of directors and a scientific advisory board of industry experts. The leadership team brings together veterans of microbial genomics, drug discovery and biologics manufacturing, underscoring the company’s strategic focus on translating microbiome insights into safe, effective therapies for unmet medical needs worldwide.
AI Generated. May Contain Errors.
Free PHGE Stock Alerts